In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Virco's HIV resistance test approved in Europe

This article was originally published in Clinica

Executive Summary

Infectious disease diagnostic specialist Virco has CE marked its vircoTYPE HIV-1 resistance test for sale in Europe. It is designed to predict how susceptible a patient's virus is to certain classes of HIV drugs, the reverse transcriptase and protease inhibitors. First, the referring lab genetically sequences the virus and sends the results to Virco, which evaluates the mutations and performs mathematical modelling using the vircoTYPE HIV-1 software to predict the patient's response to a given drug. This could help physicians tailor treatment more effectively. The Beerse, Belgium-based company claims the product is the only HIV diagnostic of its kind to be available in Europe. Virco is also developing a test to predict response to another type of HIV drug, the integrase inhibitors, called vircoTYPE HIV-1 IN.






Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts